{
    "info": {
        "nct_id": "NCT02574455",
        "official_title": "An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments",
        "inclusion_criteria": "* Histologically or cytologically confirmed TNBC based on the most recent analyzed biopsy or other pathology specimen. Triple negative is defined as <1% expression for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) by in-situ hybridization.\n* Refractory to or relapsed after at least two prior standard therapeutic regimens for advanced/metastatic TNBC.\n* Prior exposure to a taxane in localized or advanced/metastatic setting.\n* Eligible for one of the chemotherapy options listed as TPC (eribulin, capecitabine, gemcitabine, or vinorelbine) as per investigator assessment.\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.\n* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Bone-only disease is not permitted.\n* At least 2 weeks beyond prior anti-cancer treatment (chemotherapy, endocrine therapy, radiotherapy, and/or major surgery), and recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy).\n* At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks).\n* Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, absolute neutrophil count (ANC) > 1,500 per mm^3, platelets > 100,000 per mm^3).\n* Adequate renal and hepatic function (creatinine clearance [CrCL] > 60 mL/min, bilirubin ≤ 1.5 institutional upper limit of normal [IULN], aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin ≥3 g/dL).\n* Recovered from all toxicities to Grade 1 or less by National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) v4.03 (except alopecia or peripheral neuropathy that may be Grade 2 or less) at the time of randomization. Participants with Grade 2 neuropathy are eligible but may not receive vinorelbine as TPC.\n* Participants with treated, non-progressive brain metastases, off high-dose steroids (>20 mg prednisone or equivalent) for at least 4 weeks can be enrolled in the trial.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Women who are pregnant or lactating.\n* Women of childbearing potential or fertile men unwilling to use effective contraception during study and up to three months after treatment discontinuation in women of child-bearing potential and six months in males post last study drug.\n* Participants with Gilbert's disease.\n* Participants with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while participants with other prior malignancies must have had at least a 3-year disease-free interval.\n* Participants known to be human immunodeficiency (HIV) positive, hepatitis B positive, or hepatitis C positive.\n* Infection requiring antibiotic use within one week of randomization.\n* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal and hepatic function (creatinine clearance [CrCL] > 60 mL/min, bilirubin ≤ 1.5 institutional upper limit of normal [IULN], aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin ≥3 g/dL).",
            "criterions": [
                {
                    "exact_snippets": "creatinine clearance [CrCL] > 60 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bilirubin ≤ 1.5 institutional upper limit of normal [IULN]",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "IULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "IULN"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "IULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "IULN"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "IULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum albumin ≥3 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recovered from all toxicities to Grade 1 or less by National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) v4.03 (except alopecia or peripheral neuropathy that may be Grade 2 or less) at the time of randomization. Participants with Grade 2 neuropathy are eligible but may not receive vinorelbine as TPC.",
            "criterions": [
                {
                    "exact_snippets": "Recovered from all toxicities to Grade 1 or less by National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) v4.03 ... at the time of randomization.",
                    "criterion": "toxicities (by NCI CTCAE v4.03)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia or peripheral neuropathy that may be Grade 2 or less",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia or peripheral neuropathy that may be Grade 2 or less",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with Grade 2 neuropathy are eligible but may not receive vinorelbine as TPC.",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "vinorelbine as TPC eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to a taxane in localized or advanced/metastatic setting.",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to a taxane",
                    "criterion": "taxane exposure",
                    "requirements": [
                        {
                            "requirement_type": "history of exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in localized or advanced/metastatic setting",
                    "criterion": "disease setting of taxane exposure",
                    "requirements": [
                        {
                            "requirement_type": "setting",
                            "expected_value": [
                                "localized",
                                "advanced/metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1",
                    "criterion": "ECOG performance score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with treated, non-progressive brain metastases, off high-dose steroids (>20 mg prednisone or equivalent) for at least 4 weeks can be enrolled in the trial.",
            "criterions": [
                {
                    "exact_snippets": "treated, non-progressive brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated"
                        },
                        {
                            "requirement_type": "progression status",
                            "expected_value": "non-progressive"
                        }
                    ]
                },
                {
                    "exact_snippets": "off high-dose steroids (>20 mg prednisone or equivalent) for at least 4 weeks",
                    "criterion": "steroid use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "mg prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "duration off steroids",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed TNBC based on the most recent analyzed biopsy or other pathology specimen. Triple negative is defined as <1% expression for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) by in-situ hybridization.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed TNBC",
                    "criterion": "TNBC (triple negative breast cancer)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "most recent analyzed biopsy or other pathology specimen",
                    "criterion": "specimen recency",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "most recent"
                        }
                    ]
                },
                {
                    "exact_snippets": "<1% expression for estrogen receptor (ER)",
                    "criterion": "estrogen receptor (ER) expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "<1% expression for ... progesterone receptor (PR)",
                    "criterion": "progesterone receptor (PR) expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "negative for human epidermal growth factor receptor 2 (HER2) by in-situ hybridization",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "in-situ hybridization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refractory to or relapsed after at least two prior standard therapeutic regimens for advanced/metastatic TNBC.",
            "criterions": [
                {
                    "exact_snippets": "Refractory to ... at least two prior standard therapeutic regimens for advanced/metastatic TNBC",
                    "criterion": "response to prior standard therapeutic regimens for advanced/metastatic TNBC",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed after at least two prior standard therapeutic regimens for advanced/metastatic TNBC",
                    "criterion": "response to prior standard therapeutic regimens for advanced/metastatic TNBC",
                    "requirements": [
                        {
                            "requirement_type": "relapse",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 2 weeks beyond prior anti-cancer treatment (chemotherapy, endocrine therapy, radiotherapy, and/or major surgery), and recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy).",
            "criterions": [
                {
                    "exact_snippets": "At least 2 weeks beyond prior anti-cancer treatment (chemotherapy, endocrine therapy, radiotherapy, and/or major surgery)",
                    "criterion": "time since prior anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy)",
                    "criterion": "acute toxicities from prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "alopecia",
                                "peripheral neuropathy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks).",
            "criterions": [
                {
                    "exact_snippets": "At least 2 weeks beyond high dose systemic corticosteroids",
                    "criterion": "high dose systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks",
                    "criterion": "low dose corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 20,
                                "unit": "mg prednisone or equivalent daily"
                            }
                        },
                        {
                            "requirement_type": "dose stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible for one of the chemotherapy options listed as TPC (eribulin, capecitabine, gemcitabine, or vinorelbine) as per investigator assessment.",
            "criterions": [
                {
                    "exact_snippets": "Eligible for one of the chemotherapy options listed as TPC (eribulin, capecitabine, gemcitabine, or vinorelbine)",
                    "criterion": "chemotherapy eligibility (TPC)",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "chemotherapy options",
                            "expected_value": [
                                "eribulin",
                                "capecitabine",
                                "gemcitabine",
                                "vinorelbine"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, absolute neutrophil count (ANC) > 1,500 per mm^3, platelets > 100,000 per mm^3).",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematology without ongoing transfusional support",
                    "criterion": "hematology",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "transfusional support",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin > 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "absolute neutrophil count (ANC) > 1,500 per mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1500,
                                "unit": "per mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelets > 100,000 per mm^3",
                    "criterion": "platelets",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100000,
                                "unit": "per mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Bone-only disease is not permitted.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        },
                        {
                            "requirement_type": "criteria_version",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Bone-only disease is not permitted",
                    "criterion": "bone-only disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Infection requiring antibiotic use within one week of randomization.",
            "criterions": [
                {
                    "exact_snippets": "Infection requiring antibiotic use within one week of randomization",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring antibiotic use"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week before randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or lactating.",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with Gilbert's disease.",
            "criterions": [
                {
                    "exact_snippets": "Participants with Gilbert's disease.",
                    "criterion": "Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential or fertile men unwilling to use effective contraception during study and up to three months after treatment discontinuation in women of child-bearing potential and six months in males post last study drug.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential or fertile men unwilling to use effective contraception during study and up to three months after treatment discontinuation in women of child-bearing potential and six months in males post last study drug.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use of effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration (women of childbearing potential)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "duration (fertile men)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants known to be human immunodeficiency (HIV) positive, hepatitis B positive, or hepatitis C positive.",
            "criterions": [
                {
                    "exact_snippets": "Participants known to be human immunodeficiency (HIV) positive",
                    "criterion": "HIV infection status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B positive",
                    "criterion": "hepatitis B infection status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C positive",
                    "criterion": "hepatitis C infection status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.",
            "criterions": [
                {
                    "exact_snippets": "Other concurrent medical or psychiatric conditions",
                    "criterion": "concurrent medical or psychiatric conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator opinion of confounding or prevention",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while participants with other prior malignancies must have had at least a 3-year disease-free interval.",
            "criterions": [
                {
                    "exact_snippets": "Participants with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible",
                    "criterion": "history of non-melanoma skin cancer or carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants with other prior malignancies must have had at least a 3-year disease-free interval",
                    "criterion": "history of other prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "disease-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "Note: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}